case_images: PMC10680256_01
case_images: Preoperative imaging of the pulmonary nodules and abdominal mass. (A) Thoracic radiographic image shows the presence of numerous pulmonary nodules with diameters ranging from 5 to 11 mm, which are distributed extensively throughout the lung field. Identifiable pulmonary nodules are indicated by white arrows. (B) Abdominal radiographic image shows a soft tissue opacity in the region of the right kidney (white arrowheads). (C) Abdominal ultrasound image shows a large (53.8 x 37.0 mm), heterogenous mass (yellow arrowheads) arising from the cranial pole of the right kidney. The right kidney is accompanied by an active vascular response on E-flow (yellow arrow). LL, left lateral view.
case_images: fvets-10-1287185-g001.jpg
case_images: PMC10680256_01_fvets-10-1287185-g001.jpg
case_images: fig1
case_images: Thoracic radiography images showed multiple pulmonary nodules of different sizes ranging from 5 to 11 mm, with a maximum size of 11.4 x 8.8 mm (Figures 1A, 2A). Abdominal radiography revealed a soft tissue opacity between the 13th thoracic vertebra (T13) and the third lumbar vertebra (L3) in the lateral view (Figure 1B). Additionally, abdominal ultrasound revealed a heterogeneous mass, 53.8 x 37.9 mm in size, arising from the cranial pole of the right kidney with a vigorous blood flow response on E-flow (Figure 1C). The results demonstrated that among sorafenib, imatinib, doxorubicin, carboplatin, and toceranib (Palladia , Zoetis, Florham Park, NJ, United States), toceranib showed the most potent cytotoxic effect (Supplementary Figure S1).
case_images: Changes in the pulmonary nodules on thoracic radiographs from before toceranib administration to 2 weeks, 2 months, and 4 months after treatment initiation. Pulmonary nodules with well-defined borders are indicated by white arrows, whereas regressed nodules are indicated by yellow dashed arrows. (A) Prior to toceranib administration, multiple pulmonary nodules with soft tissue opacity are observed throughout the generalized lung field. The pulmonary nodule with the largest size measures 11.4 x 8.8 mm. (B) In a thoracic radiograph obtained 2 weeks after toceranib administration, the previously identified pulmonary nodule with the largest size is no longer visible in the lateral view. The largest measurable diameter of the remaining nodule is approximately 9 mm. (C) In a thoracic radiograph obtained 2 months after toceranib administration, another pulmonary nodule initially sized 8.4 x 7.7 mm is no longer detected. The majority of the pulmonary nodules exhibit partial remission and a diminished size. (D) In a thoracic radiograph obtained 4 months after toceranib administration, no further remission is observed in the existing pulmonary nodules. Indications of newly detected nodules or the recurrence of previously diminished pulmonary nodules are also not found.
case_images: fvets-10-1287185-g002.jpg
case_images: PMC10680256_01_fvets-10-1287185-g002.jpg
case_images: fig2
case_images: Thoracic radiography images showed multiple pulmonary nodules of different sizes ranging from 5 to 11 mm, with a maximum size of 11.4 x 8.8 mm (Figures 1A, 2A). Serial changes in the pulmonary nodules following the administration of toceranib are shown in Figure 2. Pulmonary nodules, suspected to be metastases of renal cell carcinoma, exhibited a decrease in size and opacity on thoracic radiography, accompanied by blurring of their borders (Figure 2B). On thoracic radiography, most of the pulmonary nodules exhibited partial remission and had diminished in size (Figure 2C). Nevertheless, there were no signs of recurrence in those that had previously shown remission, and no additional nodules were detected (Figure 2D).
case_images: Gross morphological features of right renal mass in a dog with RCC. (A) Intraoperative finding of a highly vascularized renal mass with blood vessels connecting to the liver and potentially functioning as feeding vessels (arrow). Numerous tortuous vessels are found to have surrounded the capsule of the mass. (B) Surgically removed mass of size 50 x 65 mm, with a lumpy bumpy parenchyma, an indistinct corticomedullary junction, and an irregular margin; findings suggest a fully tumorous transformation with total loss of normal structure. RCC, renal cell carcinoma.
case_images: fvets-10-1287185-g003.jpg
case_images: PMC10680256_01_fvets-10-1287185-g003.jpg
case_images: fig3
case_images: Additionally, blood vessels connecting the tumor to the liver were identified and suspected to function as feeding vessels (Figure 3A). The excised tissue samples were subjected to histopathologic evaluation (Figure 3B), which confirmed that the renal mass represented papillary RCC with incomplete excision margins (Figure 4A).
case_images: Histopathological features of the right renal mass in a dog with a papillary RCC. (A) Histological section showing a papillary RCC. The tumor consists of densely packed, well-defined, and non-encapsulated neoplastic polygonal cells arranged in a palisading pattern. The neoplastic cells form ducts, papillary projections, and lobules on a fine fibrovascular stroma. H&E staining: magnification, 100x; scale bar, 100 mum. (B) The tumor cells exhibit dense chromatin and 1-4 prominent nucleoli (dashed arrow) with variably distinct cell borders, moderate-to-scant eosinophilic cytoplasm, and regional vacuolization. Moderate anisocytosis and anisokaryosis are observed with a high number of mitotic figures (arrows; 66 in 10 high-power fields). H&E staining: magnification, 400x; scale bar, 20 mum. RCC, renal cell carcinoma; H&E, hematoxylin & eosin.
case_images: fvets-10-1287185-g004.jpg
case_images: PMC10680256_01_fvets-10-1287185-g004.jpg
case_images: fig4
case_images: The excised tissue samples were subjected to histopathologic evaluation (Figure 3B), which confirmed that the renal mass represented papillary RCC with incomplete excision margins (Figure 4A). Histopathological examination revealed high malignancy with dense chromatin, prominent nucleoli, and numerous mitotic figures (66 in 10 high-power fields; Figure 4B).